Key result
Low pulse pressure amplification predicts ~460% higher risk of renal endpoints in stage 4 CKD.
Why the study?
Does aortic to brachial pulse pressure amplification predict renal function loss in patients with chronic kidney disease?
Cohort (n=217)
Does aortic to brachial pulse pressure amplification predict renal function loss in patients with chronic kidney disease?
Hazard Ratio: 5.6 (95% CI 1.5–21.9)
p-value: p=<.001
Aortic to brachial pulse pressure amplification is reduced in CKD and serves as an independent predictor of severe renal endpoints in patients with advanced CKD.
May aid risk stratification in stage 4 CKD; extends vascular marker observations but leaves open causal validation.
Pulse pressure amplification (PPA) reflects large artery function. Its contribution in chronic kidney disease (CKD) remains uncertain. The authors assessed PPA in CKD progression in patients with CKD stage 2 to 4 (n=128) and 89 controls (follow-up: 42 months). PPA was reduced in CKD patients as compared with control patients and associated with decline in renal function. Sixteen renal endpoints, defined by 50% loss of renal function or start of renal replacement therapy, were detected. In Cox regression analysis, PPA, estimated glomerular filtration rate, and proteinuria predicted renal endpoints. Patients with CKD stage 4 and low PPA had the highest risk for developing renal endpoints (unadjusted 8.1; 2.4-27.7 and adjusted for age and proteinuria 5.6; 1.5-21.9, log-rank P<.001). Taken together, PPA is reduced in CKD and is associated with declining renal function. In addition, low PPA predicts renal endpoints in severe CKD. Furthermore, this study emphasizes the role of systolic blood pressure as a major determinant of PPA.
No takes yet. Share an insight, caveat, or question.
Wassertheurer et al. (2014) conducted a cohort in Chronic Kidney Disease (n=217). Low pulse pressure amplification vs. High pulse pressure amplification / Controls was evaluated on 50% loss of renal function or start of renal replacement therapy (HR 5.6, 95% CI 1.5-21.9, p=<.001). Low pulse pressure amplification in patients with stage 4 chronic kidney disease predicted a higher risk of renal endpoints (adjusted HR 5.6; 95% CI 1.5-21.9; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: